AMD	Age-related macular degeneration
AT	Artificial tears
BEVA	Bevacizumab
CD44	Cluster determinant 44
CH	Chitosan
CRN	L-carnitine
Cx43	MP Connexin 43 mimetic peptide
CyA	Cyclosporine A
DEAEM	2-(diethylamino) ethyl methacrylate
DED	Dry eye disease
DEX	Dexamethasone
DEX-SP	Dexamethasone sodium phosphate
DLVO	Derjaguin, Landau, Verwey, and Overbeek
ECM	Extracellular matrices
EDL	Electrical double layer
EGCG	Epigallocatechin gallate
EPR	Enhanced permeation and retention
FA	Ferulic acid
FLZ	Fluconazole
GEH	Gelatin–EGCG nanoparticles
HA	Hyaluronic acid
HABD	HA-binding domain
HA–HC	Hyaluronic acid–heavy chain
HA-PEC	HA-based polyelectrolyte complexes
HC	Heavy chain
HCE	Human corneal epithelial
HMWHA	High-MW HA
HPMC	Hydroxypropyl methylcellulose
HYAL	Hyaluronidases
IL	Interleukin
IOBA-NHC	Spontaneously immortalised normal human conjunctival cell line
IOP	Intraocular pressure
IVI	Intravitreal injection
LMWHA	Low-MW HA
LPHNP	Lipid–polymer hybrid nanoparticles
LYVE-1	Lymphatic vessel endothelial HA receptors
MCF.HCL	Moxifloxacin hydrochloride
MCR	Molar charge ratio
MPS	Multipurpose solution
mRNA	Messenger RNA
MSVI	Moderate-to-severe visual impairment
MW	Molecular weight
NaHA	Sodium hyaluronate
NHA	Native HA
ODDS	Ocular drug delivery systems
OSDI	Ocular Surface Disease Index
PECs	Polyelectrolyte complexes
pHEMA	poly-2-hydroxyethyl methacrylate
PLGA	Poly(D, L-lactide-co-glycide)
PLL	Poly(L-lysine)
pNIPAAM	Poly(N-isopropylacrylamide)
PTM	Pentamidine isethionate
RNS	Reactive nitrogen species
ROS	Reactive oxygen species
SH	Sodium hyaluronate
SIHy	Silicone hydrogel
siRNA	Small interfering RNA
TFBT	Tear film break-up time
TLR	Toll-like receptors
TM	Timolol maleate
TNF-α	Tumour necrosis factor-α
TPP	Tripolyphosphate
TRIS	Tris (trimethylsiloxy) methacryloxy propyl silane
TSG-6	Tumour necrosis factor-stimulated gene-6
VEGF-2	Vascular endothelial growth factor 2
VEGF165	Vascular endothelial growth factor 165
VEGF	Vascular endothelial growth factor
VitE-TPGS	D-α-Tocopherolpolyethylene glycol succinate
ZP	Zeta potential